Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Effect Of Low Dose Bortezomib On Bone Formation In Smoldering Myeloma Patients

Maurizio Zangari, MD, Tamara Berno, MD, Mohamed E Salama, MD, Sherjeel Sana, MD, Giampaolo Talamo, MD, Karen Pena, Scott Miller, PhD, Fenghuang Zhan, MD&PhD

Blood (2013) 122 (21): 3204.

https://doi.org/10.1182/blood.V122.21.3204.3204

Published: 2013

Journal Articles

Phase I Exploratory Study of IV Formulation of Panobinostat in Combination with Bortezomib in Relapsed/Refractory Multiple Myeloma Patients: Effect On Serum PTH and Gene Expression Profiling (GEP) Studies

Maurizio Zangari, MD, Tamara Berno, MD, Giampaolo Talamo, MD, Xin Zhan, Wen Zhou, He Wang, Ye Yang, PhD, Jiliang Xia, Yi Zhou, Karen Pena, Leanne Lujan, Jessica Kohan, Mohamed E Salama, M.D., Fenghuang Zhan, MD, PhD

Blood (2012) 120 (21): 4073.

https://doi.org/10.1182/blood.V120.21.4073.4073

Published: 2012

Journal Articles

Sirolimus for Graft-Versus-Host-Diseases Prophylaxis in Non-Myeloablative Matched Related Transplantation: Safety and Efficacy.

Hong Zheng, MD, PhD, Michelle Carraher, BA, Eric Schaefer, M.A., Giampaolo Talamo, MD, W. Christopher Ehmann, MD, Witold Rybka, David F. Claxton, M.D.

Blood (2009) 114 (22): 4329.

https://doi.org/10.1182/blood.V114.22.4329.4329

Published: 2009

Journal Articles

G-CSF Mobilized Versus Conventional Donor Lymphocytes in the Treatment of Hematological Malignancies.

Kamal K.S. Abbi, M.D., W. Chritopher Ehmann, MD, Giampaolo Talamo, MD, Kenneth Lucas, MD, Michelle Carraher, BA, Witold Rybka, M.D., David F. Claxton

Blood (2009) 114 (22): 4301.

https://doi.org/10.1182/blood.V114.22.4301.4301

Published: 2009

Journal Articles

Long Term Survival After Sirolimus Based Non-Ablative Alternative Donor Transplantation.

Jon Karch, BSc, Eric Schaefer, M.A., W. Chritopher Ehmann, MD, Michelle Carraher, BA, Giampaolo Talamo, MD, Witold B Rybka, MD, David F. Claxton, M.D.

Blood (2009) 114 (22): 1212.

https://doi.org/10.1182/blood.V114.22.1212.1212

Published: 2009

Journal Articles

Single Autologous Stem Cell Transplant Using Busulfan and Cyclophosphamide as Conditioning Regimen in Patients with Multiple Myeloma

Giampaolo Talamo, MD, David F. Claxton, MD, Joseph Drabick, MD, David W. Dougherty, MD, Jeff Sivik, PharmD, Christopher W. Ehmann, MD, Witold Rybka, MD

Blood (2008) 112 (11): 4436.

https://doi.org/10.1182/blood.V112.11.4436.4436

Published: 2008

Journal Articles

Marked Activity of Velcade Plus Thalidomide (V+T) in Advanced and Refractory Multiple Myeloma (MM).

Maurizio Zangari, MD, Bart Barlogie, MD, PhD, Klaus Hollmig, MD, Athanasios Fassas, MD, Erik Rasmussen, Raymond Thertulien, MD, PhD, Giampaolo Talamo, MD, Choon-Kee Lee, MD, Guido Tricot, MD, PhD

Blood (2004) 104 (11): 1480.

https://doi.org/10.1182/blood.V104.11.1480.1480

Published: 2004

Journal Articles

Low Incidence of Complete Remission but Comparable Event-Free Survival(EFS) and Overall Survival (OS) with a History of Prior Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Myeloma (SMM) among Patients Receiving Total Therapy 2 (TT 2).

Athanasios Fassas, MD, Bart Barlogie, MD, PhD, Erik Rasmussen, Teresa Milner, Julian Terry, Maurizio Zangari, MD, Giampaolo Talamo, MD, Choon-Kee Lee, MD, Raymond Thertulien, MD, PhD, John Crowley, PhD, Guido Tricot, MD, PhD

Blood (2004) 104 (11): 932.

https://doi.org/10.1182/blood.V104.11.932.932

Published: 2004

Journal Articles

Total Therapy 2 (TT 2) for Newly Diagnosed Patients with Multiple Myeloma (MM): Examination of Dose Effect of Thalidomide (T) among Those Randomized to T.

Raymond Thertulien, MD, PhD, Bart Barlogie, MD, PhD, Maurizio Zangari, MD, Athanasios Fassas, MD, Julie Stover, Teresa Milner, Erik Rasmussen, Elias Anaissie, MD, PhD, Choon-Kee Lee, MD, Klaus Hollmig, MD, Giampaolo Talamo, MD, Guido Tricot, MD, PhD

Blood (2004) 104 (11): 934.

https://doi.org/10.1182/blood.V104.11.934.934

Published: 2004

Journal Articles

Safety of Total Therapy III for Newly Diagnosed Multiple Myeloma: Preliminary Analysis of 62 Consecutive Patients.

Elias J. Anaissie, MD, Marisa H. Miceli, MD, Li Dong, MD, MS, Fariba Saghafifar, MD, Giampaolo Talamo, MD, Klaus A. Hollmig, MD, Guido Tricot, MD, Bart Barlogie, MD, PhD.

Blood (2004) 104 (11): 935.

https://doi.org/10.1182/blood.V104.11.935.935

Published: 2004

Journal Articles

Avascular Necrosis of Bone after Therapy for Multiple Myeloma: A Study of 561 Consecutive Patients.

Elias J. Anaissie, MD, Giampaolo Talamo, MD, Edgardo Angtuaco, MD, Ronald C. Walker, MD, Li Dong, MD, MS, Maurizio Zangari, MD, Guido Tricot, MD, Bart Barlogie, MD, PhD.

Blood (2004) 104 (11): 3467.

https://doi.org/10.1182/blood.V104.11.3467.3467

Published: 2004

Journal Articles

Protective Effect of VELCADE® on Thalidomide-Associated Deep Vein Thrombosis (DVT).

Maurizio Zangari, MD, Bart Barlogie, MD, PhD, Choon-Kee Lee, MD, Annick E. Tricot, Athanasios Fassas, MD, Elias Anaissie, MD, Klaus Hollmig, MD, Raymond Thertulien, MD, Giampaolo Talamo, MD, Frits van Rhee, MD, PhD, Julie M. Stover, BA, Louis Fink, MD, Guido J. Tricot, MD, PhD

Blood (2004) 104 (11): 4914.

https://doi.org/10.1182/blood.V104.11.4914.4914

Published: 2004

Journal Articles

Bortezomib (Velcade™) + Adriamycin™ + Thalidomide + Dexamethasone (VATD) as an Effective Regimen in Patients with Refractory or Relapsed Multiple Myeloma (MM).

Klaus Hollmig, MD, Julie Stover, BA, Giampaolo Talamo, MD, Athanasios Fassas, MD, Choon-Kee Lee, MD, Elias Anaissie, MD, Guido Tricot, MD, PhD, Bart Barlogie, MD, PhD

Blood (2004) 104 (11): 2399.

https://doi.org/10.1182/blood.V104.11.2399.2399

Published: 2004

Journal Articles

Metaphase Cytogenetic Abnormalities (M-CA) and Interphase FISH for Deletion 13 (FISH 13) in Total Therapy 2 (TT 2): Follow up Observation among? 380 Patients with Newly Diagnosed Multiple Myeloma (MM).

John Shaughnessy, PhD, Frank Zhan, PhD, Bart Barlogie, MD, PhD, Erik Rasmussen, Teresa Milner, Lisa Jackson, Athanasios Fassas, MD, Maurizio Zangari, MD, Choon-Kee Lee, MD, Giampaolo Talamo, MD, Raymond Thertulien, MD, PhD, John Crowley, PhD, Guido Tricot, MD, PhD

Blood (2004) 104 (11): 4935.

https://doi.org/10.1182/blood.V104.11.4935.4935

Published: 2004

Journal Articles

Daily C - Reactive Protein (CRP) Levels Allow Early Identification of Patients with Severe Complications after Melphalan (MEL) and Autologous Stem Cell Transplantation (ASCT) for Multiple Myeloma (MM).

Elias J. Anaissie, MD, Monica L. Grazziutti, MD, Athanasios Fassas, MD, Li Dong, MD, Miceli H. Miceli, MD, Frits Van Rhee, MD, PhD, Klaus A. Hollmig, MD, Giampaolo Talamo, MD, Guido J. Tricot, MD, Bart Barlogie, MD

Blood (2004) 104 (11): 5040.

https://doi.org/10.1182/blood.V104.11.5040.5040

Published: 2004

Journal Articles

Increased Bone Marrow Iron Stores, Severe Mucositis and Large Area under the Curve (AUC) of Profound Neutropenia Predict Severe Infection in 382 Myeloma Patients Undergoing Melphalan - Autologous Stem Cell Transplantation (MEL-ASCT).

Elias J. Anaissie, MD, Marisa H. Miceli, MD, Li Dong, MD,MS, Monica L. Grazziutti, MD, Sabitha Rajan, Giampaolo Talamo, MD, Raymond Thertulien, MD, PhD, Anasthasios Fassas, MD, Guido Tricot, MD, Bart Barlogie, MD, PhD

Blood (2004) 104 (11): 1158.

https://doi.org/10.1182/blood.V104.11.1158.1158

Published: 2004

NARROW

Effect Of Low Dose Bortezomib On Bone Formation In Smoldering Myeloma Patients

Phase I Exploratory Study of IV Formulation of Panobinostat in Combination with Bortezomib in Relapsed/Refractory Multiple Myeloma Patients: Effect On Serum PTH and Gene Expression Profiling (GEP) Studies

Sirolimus for Graft-Versus-Host-Diseases Prophylaxis in Non-Myeloablative Matched Related Transplantation: Safety and Efficacy.

G-CSF Mobilized Versus Conventional Donor Lymphocytes in the Treatment of Hematological Malignancies.

Long Term Survival After Sirolimus Based Non-Ablative Alternative Donor Transplantation.

Single Autologous Stem Cell Transplant Using Busulfan and Cyclophosphamide as Conditioning Regimen in Patients with Multiple Myeloma

Marked Activity of Velcade Plus Thalidomide (V+T) in Advanced and Refractory Multiple Myeloma (MM).

Low Incidence of Complete Remission but Comparable Event-Free Survival(EFS) and Overall Survival (OS) with a History of Prior Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Myeloma (SMM) among Patients Receiving Total Therapy 2 (TT 2).

Total Therapy 2 (TT 2) for Newly Diagnosed Patients with Multiple Myeloma (MM): Examination of Dose Effect of Thalidomide (T) among Those Randomized to T.

Safety of Total Therapy III for Newly Diagnosed Multiple Myeloma: Preliminary Analysis of 62 Consecutive Patients.

Avascular Necrosis of Bone after Therapy for Multiple Myeloma: A Study of 561 Consecutive Patients.

Protective Effect of VELCADE® on Thalidomide-Associated Deep Vein Thrombosis (DVT).

Bortezomib (Velcade™) + Adriamycin™ + Thalidomide + Dexamethasone (VATD) as an Effective Regimen in Patients with Refractory or Relapsed Multiple Myeloma (MM).

Metaphase Cytogenetic Abnormalities (M-CA) and Interphase FISH for Deletion 13 (FISH 13) in Total Therapy 2 (TT 2): Follow up Observation among? 380 Patients with Newly Diagnosed Multiple Myeloma (MM).

Daily C - Reactive Protein (CRP) Levels Allow Early Identification of Patients with Severe Complications after Melphalan (MEL) and Autologous Stem Cell Transplantation (ASCT) for Multiple Myeloma (MM).

Increased Bone Marrow Iron Stores, Severe Mucositis and Large Area under the Curve (AUC) of Profound Neutropenia Predict Severe Infection in 382 Myeloma Patients Undergoing Melphalan - Autologous Stem Cell Transplantation (MEL-ASCT).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only